- Home
- IKT
as 11-08-2024 1:34pm EST
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease ("PD"), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.
Upcoming Earnings Alert:
Get ready for potential market movements as Inhibikase Therapeutics Inc. IKT prepares to release earnings report on 12 Nov 2024.
| Founded: | 2008 | Country: | United States |
| Employees: | N/A | City: | ATLANTA |
| Market Cap: | 159.2M | IPO Year: | 2020 |
| Target Price: | $5.00 | AVG Volume (30 days): | 318.4K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.14 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.80 - $3.82 | Next Earning Date: | 11-12-2024 |
| Revenue: | $79,570 | Revenue Growth: | -68.40% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Inhibikase Therapeutics Inc. (IKT)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Bellini Roberto | IKT | Director | Oct 21 '24 | Buy | $1.37 | 1,460,000 | $2,000,200.00 | 1,460,000 | |
| Kush Arvind | IKT | Director | Oct 21 '24 | Buy | $1.37 | 145,000 | $198,650.00 | 145,000 |
Latest Inhibikase Therapeutics Inc. News
IKT Breaking Stock News: Dive into IKT Ticker-Specific Updates for Smart Investing
TipRanks
16 days ago
Inhibikase Therapeutics Secures Funding and Strengthens Leadership
GuruFocus.com
17 days ago
Perceptive Advisors LLC Acquires New Stake in Inhibikase Therapeutics Inc
GlobeNewswire
18 days ago
Inhibikase Therapeutics Announces Closing of up to $275 Million Financing and Advancement of IkT-001Pro into a Late Stage Clinical Trial in Pulmonary Arterial Hypertension
GuruFocus.com
22 days ago
Fairmount Funds Management LLC Acquires New Stake in Inhibikase Therapeutics Inc
TipRanks
a month ago
Inhibikase Therapeutics Secures $110M for Drug Development
GuruFocus.com
a month ago
Steven Cohen's Strategic Acquisition of Inhibikase Therapeutics Shares
TipRanks
a month ago
Inhibikase Therapeutics Unveils PAH and Parkinson’s Drug Pipeline
MT Newswires
a month ago
Inhibikase Therapeutics Prices $110 Million Private Placement; Shares Jump
Compare IKT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "IKT Inhibikase Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.